Home Tags Immunotherapy

Tag: Immunotherapy

Pyxis Oncology to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary...

The US Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications from Cambridge, Massachusetts-based biotech Pyxis Oncology, allowing the company to...

BYON4228 Enhances Anti-tumor Immunity In Vitro

CD47, an immunoglobulin also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on the surface of normal, healthy, hematopoietic stem cells (HSC)...

Immunomedics and Roche Expand Study Collaboration in First-line Metastatic Triple-negative Breast...

Immunomedics and Roche have agreed to expand their clinical trial collaboration to evaluate sacituzumab govitecan-hziy (Trodelvy™), a Trop-2-directed antibody conjugated to a topoisomerase I...

Novel Approach may Limit the Troubling Side Effects of Cancer Immunotherapy

Connecting highly effective cancer immunotherapy drugs such as anti-CTLA4 (ipilimumab | Yervoy®; Bristol-Myers Squibb Company) and anti-PD-L1 (atezolizumab | Tecentriq®; Genentech) to peptides that...

ECCO2017: Truly Multidisciplinary and Genuinely Practice-changing

In late January, ECCO2017: European Cancer Congress will be held in Amsterdam, The Netherlands. The organizers promote the meeting as the only truly multidisciplinary...

The Clinical Landscape of Antibody-drug Conjugates

Antibody drug conjugates (ADCs) are a class of therapeutics that combine the selective targeting properties of monoclonal antibodies (mAbs) with potent cell killing activities of cytotoxic agents. Given rapid pace of progress in this field, it is important for drug developers to have a high level view of the landscape of ADCs in the clinic. This review analyzes ADCs tested in the field of Oncology. Trials are evaluated by cancer type, trial status, phase, and characteristics of the ADC.

Challenges and Strategies for the Downstream Processing of BiSpecific Antibodies (BsAbs)

Baeuerle and Raum present an extensive review of BsAbs in their article. [2] BsAbs are most commonly used for cancer immunotherapy where they are targeted to simultaneously bind to a cytotoxic cell as well as a target tumor cell to be destroyed. Targeting two antigens simultaneously can be a promising approach. This paper will include a review of the challenges associated with the manufacturing of BsAbs in mammalian cell cultures, and the strategies that can be implemented to overcome treatment challenges.

Making Hot ADCs

Guided by a specific monoclonal antibody (mAb), antibody drug conjugates or ADC are a new, emerging, class of drugs able to deliver a drug payload directly to an intended target. This approach has recently been boosted by the U.S. Food and Drug Administration approval of brentuximab vedotin (Adcetris®; Seattle Genetics) to treat Hodgkin’s lymphoma and ado-trastuzumab emtansine (Kadcyla®; Genentech) for metastatic breast cancer. These new biotherapeutic drugs will bring many regulatory issues to the forefront regarding the ADME (Absorption, Distribution, Metabolism and Excretion) profile of each ADC. In this article, the authors discuss this and other important aspects of antibody-drug conjugates.

X